Understanding Langerhans Cell Histiocytosis: From Pathogenesis to Management

Langerhans Cell Histiocytosis (LCH) is a very uncommon clonal neoplastic disorder that features abnormal proliferation of Langerhans cells. Its manifestations range from self-limiting and single-system involvements to potentially life-threatening manifestations with multiorgan involvement. Researchers are increasingly associating the pathogenesis of LCH with mutations of the MAPK/ERK signaling pathway, especially mutations BRAF V600E and MAP2K1, and an immune dysregulation involving proinflammatory cytokines. Clinically, it varies according to age and site of involvement, with bones, skin, lungs, and endocrine organs most commonly involved. Diagnosis is done by histopathology, immunohistochemistry, imaging, and molecular studies. Treatment has advanced from the use of corticosteroids and chemotherapeutic agents to more targeted therapies such as BRAF and MEK inhibitors. The prognostication depends on factors like age, genetic mutations, and organ system involvement, with recurrent possibilities, long-term complications of neurodegeneration, and endocrine dysfunction. The future promises better results through gene therapy, personalized medicine, and new immunomodulatory approaches for this multifaceted disease.